podcast
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Healthcare
Zelluna’s ZIMA-101 Phase I trial will proceed with enrolment of two more patients at the first dose level after an independent safety committee found no dose-limiting toxicities or other concerns in the first patient. The patient completed all three planned doses of ZI-MA4-1, Zelluna’s off-the-shelf MAGE-A4-targeting TCR-NK cell therapy, with no serious adverse events reported. Recruitment is continuing at The Christie and The Royal Marsden in the UK, with further clinical data expected as more patients are treated.
Financials | Comment
TMT | Comment
Healthcare | Comment
Financials | Comment
Consumer | Comment
Get access to the very latest content matched to your personal investment style.